Xeris Pharmaceuticals Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Chicago--(business wire)--xeris biopharma holdings, inc. (nasdaq: xers), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, and xeris pharmaceuticals, inc., today announced financial results for the fourth quarter and full-year 2021 and recent highlights. “during 2021, we made significant progress toward achieving critical mass and becoming a fully integrated pharmaceutical company with the acqui

Chicago--(business wire)--xeris biopharma holdings, inc. (nasdaq: xers), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that recorlev® (levoketoconazole) is now available for prescription. the u.s. food and drug administration (fda) approved recorlev on december 31, 2021 for the treatment of endogenous hypercortisolemia in adult patients with cushing's syndrome for whom surger

Chicago--(business wire)--xeris biopharma holdings, inc. (nasdaq: xers) (“xeris” or the “company”), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced a business update and reaffirmed its 2021 pro forma net sales and year-end cash balance guidance. “we are proud to have ended 2021 on a strong note with continued growth of gvoke and keveyis®, delivering net sales at the upper end o

Chicago--(business wire)--xeris biopharma holdings, inc. (nasdaq: xers) (“xeris” or the “company”), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that on january 2, 2022, it entered into a securities purchase agreement in connection with a private placement (the “private placement”) with an affiliate of armistice capital, llc (“armistice”) for aggregate gross proceeds of appr

Chicago--(business wire)--xeris biopharma holdings, inc. (nasdaq: xers), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced the u.s. food and drug administration (fda) approval of recorlev® (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with cushing's syndrome for whom surgery is not an option or has not been curative.1 “we are thrilled with

Xeris recently reported encouraging Q1 earnings. The company's commercial products are off to a strong start, including their recently launched product, Recorlev. Xeris reaffirmed its full-year net product revenue guidance to be in the range of $105M to $120M. Strongbridge synergies are expected to equal $50M by the end of this year.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Allison Wey - SVP, IR & Corporate Communications Paul Edick - Chairman & CEO Steve Pieper - CFO Conference Call Participants David Amsellem - Piper Sandler Roanna Ruiz - SVB Securities Vamil Divan - Mizuho Securities Robin Garner - Craig-Hallum Oren Livnat - H.C. Wainwright Operator Hello, and welcome to today's Xeris Biopharma's First Quarter 2022 Financial Results Conference Call and Webcast.

Xeris Biopharma Holdings, Inc. (XERS) CEO Paul Edick on Q4 2021 Results - Earnings Call Transcript

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that the Company will release its fourth quarter and full year 2021 financial results before the open of the U.S. financial markets on Thursday, March 10, 2022. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss t

Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Xeris recently updated on full-year 2021 sales, reporting that it had hit the upper end of guidance for Gvoke and Keveyis.

Xeris Biopharma Holdings Inc (NASDAQ: XERS) has reaffirmed its preliminary 2021 pro forma sales at a high-end of $76 million - $80 million guidance, approximately 55% growth from 2020. The company held year-end 2021 preliminary cash, cash equivalents, and investments of approximately $102 million.

Find out what's moving markets on the last day of the year.

The FDA approved Recorlev for the treatment of endogenous Cushing's syndrome.

The FDA approved Xeris' Recorlev drug for certain adult patients with Cushing's syndrome, sending XERS stock higher. The post XERS Stock Pops on Huge FDA News.